Last update 19 Jul 2024

Pralatrexate

Last update 19 Jul 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(2S)-2-((4-((1RS)-1-((2,4-Diaminopteridin-6-yl)methyl)but-3-ynyl)benzoyl)amino)pentanedioic acid, (2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic acid, 10-Propargyl-10-deazaaminopterin

+ [7]

Target

DHFR

Mechanism

DHFR inhibitors(Dihydrofolate reductase inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]

Active Indication

Peripheral T-Cell LymphomaPeripheral T-cell lymphoma unspecified recurrentPeripheral T-cell lymphoma unspecified refractory

Inactive Indication

Adenocarcinoma of EsophagusAnaplastic Large-Cell LymphomaB-Cell Lymphoma+ [17]

Originator Organization

Memorial Sloan Kettering Cancer Center

Active Organization

Allos Therapeutics, Inc.

Mundipharma International Ltd.Mundipharma Medical Co.

+ [5]

Inactive Organization

Spectrum Pharmaceuticals, Inc.

Memorial Sloan Kettering Cancer CenterAllos Therapeutics Ltd.

Drug Highest PhaseApproved

First Approval Date

US (24 Sep 2009),

Peripheral T-Cell Lymphoma

RegulationAccelerated Approval (US), Orphan Drug (US), Orphan Drug (EU), Priority Review (CN), Conditional marketing approval (CN), Orphan Drug (JP)

Structure

Molecular FormulaC23H23N7O5

InChIKeyOGSBUKJUDHAQEA-WMCAAGNKSA-N

CAS Registry146464-95-1

Clinical Trials associated with Pralatrexate

NCT06072131 / RecruitingPhase 3

A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients With Peripheral T-Cell Lymphoma

Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for part 2 study.
Part 2 (Efficacy and Safety): This is a 3 Arm study. Patients with previously untreated PTCL will be randomized 1:1:1 into 1 of 3 treatment groups: 2 experimental treatment groups (Bel-CHOP or Fol-COP) or 1 active comparator treatment group (CHOP). Patients will be treated for up to 6 cycles. The primary objective is to compare the Progression Free Survival of patients with newly diagnosed PTCL treated for up to 6 cycles with Beleodaq (belinostat) in combination with CHOP (Bel-CHOP) or Folotyn (pralatrexate injection) in combination with COP (Fol-COP) to CHOP alone.

Start Date04 Oct 2023

Sponsor / Collaborator

Acrotech Biopharma LLCStartup

NCT03240211 / RecruitingPhase 1IIT

Novel Immuno-epigenetic Based Platform for Patients With Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL): an International Phase Ib Study of Pembrolizumab Combined With Decitabine and/or Pralatrexate

This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs) and to evaluate the clinical efficacy at the MTD of various combinations of pembrolizumab, pralatrexate and decitabine.

Start Date02 Feb 2022

Sponsor / Collaborator

University of Virginia

[+2]

NCT03719105 / RecruitingEarly Phase 1IIT

Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lymphoma/Leukemia in Children, Adolescents and Young Adults; A NK/T-Cell Lymphoma/Leukemia Consortium Study

Patients are in 2 cohorts:
Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and young adults with advanced stage NK lymphoma and leukemia Cohort 2: combining pralatrexate (PRX) (Cycles 1, 2, 4, 6) and brentuximab vedotin (BV) (Cycles 3, 5) to cyclophosphamide, doxorubicin, and prednisone in children, adolescent, and young adults with advanced peripheral T-cell lymphoma (non-anaplastic large cell lymphoma or non-NK lymphoma/leukemia) .
Both groups proceed to allogeneic stem cell transplant with disease response.

Start Date01 Mar 2019

Sponsor / Collaborator

New York Medical College

[+1]

100 Clinical Results associated with Pralatrexate

100 Translational Medicine associated with Pralatrexate

100 Patents (Medical) associated with Pralatrexate

410

Literatures (Medical) associated with Pralatrexate

01 Feb 2024·International journal of biological macromolecules

Electrospun polydioxanone/fucoidan blend nanofibers loaded with anti-cancer precipitate from Jaspis diastra and paclitaxel: Physico-chemical characterization and in-vitro screening

Article

Author: Ramanjooloo, Avin ; Goonoo, Nowsheen ; Bhaw-Luximon, Archana ; Chummun Phul, Itisha

Nanofibers for drug delivery systems have gained much attention during the past years. This paper describes for the first time the loading of a bioactive precipitate (JAD) from the marine sponge Jaspis diastra in PDX and fucoidan-PDX. JAD was characterized by LC-MS/MS and the major component was jaspamide (1) with a purity of 62.66 %. The cytotoxicity of JAD was compared with paclitaxel (PTX). JAD and PTX displayed IC₅₀ values of 1.10 ± 0.7 μg/mL and 0.21 ± 0.12 μg/mL on skin fibroblasts L929 cells whilst their IC₅₀ values on uveal MP41 cancer cells, were 2.10 ± 0.55 μg/mL and 1.38 ± 0.68 μg/mL, respectively. JAD was found to be less cytotoxic to healthy fibroblasts compared to PTX. JAD and PTX loaded scaffolds showed sustained release over 96 h in physiological medium which is likely to reduce the secondary cytotoxic effect induced by JAD and PTX alone. The physico-chemical properties of the loaded and unloaded scaffolds together with their degradation and action on tumor microenvironment by using L929 and MP41 cells were investigated. JAD and PTX at a concentration of 0.5 % (drug/polymer, w/w) in the electrospun mats prevented growth and proliferation of L929 and MP41 cells. Co-culture of L929 and MP41 showed that the JAD and PTX loaded mats inhibited the growth of both cells and caused cell death.

23 Jan 2024·Blood advances

Pralatrexate injection combined with CHOP for treatment of PTCL: results from the Fol-CHOP dose-finding phase 1 trial

Article

Author: Barta, Stefan K ; Iyer, Swaminathan P ; Johnston, Patrick B

Abstract:

Pralatrexate is a folate antagonist that selectively enters cells expressing reduced folate carrier type 1 and competitively inhibits dihydrofolate reductase, leading to interruption of RNA synthesis, DNA replication, and apoptosis. This phase 1 study was conducted to evaluate the maximum tolerated dose (MTD) of pralatrexate in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen (part 1) and the response and pharmacokinetics of 6 cycles of this combination (CHOP + Folotyn 30 mg/m2 [Fol-CHOP]) in patients with newly diagnosed peripheral T-cell lymphoma (PTCL). In part 1, on days 1 and 8 of each cycle, patients were treated with 10, 15, 20, 25, or 30 mg/m2 of pralatrexate in combination with CHOP, per dose escalation, in 5 sequential cohorts. No patients experienced DLTs in cohorts 1, 2, 3, 4, and 5. The pralatrexate dose of 30 mg/m2 was selected to be combined with CHOP for part 2 and administered to 33 additional patients in the expansion cohort. At the MTD, the Fol-CHOP regimen was generally well tolerated in patients with PTCL, with an overall response rate (ORR) of 83.9% (20 complete response and 6 partial response), as assessed by treating investigators. Thirty-five patients (67.3%) experienced grade 3/4 treatment-emergent adverse events, the most common of which were anemia (21.2%), neutropenia (19.2%), febrile neutropenia (11.5%), fatigue, mucosal inflammation, nausea, and vomiting (7.7% each). In conclusion, Fol-CHOP was found to be a safe and effective treatment for newly diagnosed PTCL and deemed worthy of further investigation. This trial was registered at www.ClinicalTrials.gov as #NCT02594267.

01 Jan 2024·Antiviral research

Pralatrexate inhibited the replication of varicella zoster virus and vesicular stomatitis virus: An old dog with new tricks

Article

Author: Nawaz, Waqas ; Zhu, Haotian ; Lyu, Ruining ; Zhang, Fang ; Tao, Hongji ; Jiang, Na ; Cai, Yurong ; Wu, Jing ; Chen, Deyan ; You, Qiao ; Wu, Zhiwei ; Qian, Yajie

Varicella zoster virus (VZV) is associated with herpes zoster (HZ) or herpes zoster ophthalmicus (HZO). All antiviral agents currently licensed for the management of VZV replication via modulating different mechanisms, and the resistance is on the rise. There is a need to develop new antiviral agents with distinct mechanisms of action and adequate safety profiles. Pralatrexate (PDX) is a fourth-generation anti-folate agent with an inhibitory activity on folate (FA) metabolism and has been used as an anti-tumor drug. We observed that PDX possessed potent inhibitory activity against VZV infection. In this study, we reported the antiviral effects and the underlying mechanism of PDX against VZV infection. The results showed that PDX not only inhibited VZV replication in vitro and in mice corneal tissues but also reduced the inflammatory response and apoptosis induced by viral infection. Furthermore, PDX treatment showed a similar anti-VSV inhibitory effect in both in vitro and in vivo models. Mechanistically, PDX inhibited viral replication by interrupting the substrate supply for de novo purine and thymidine synthesis. In conclusion, this study discovered the potent antiviral activity of PDX with a novel mechanism and presented a new strategy for VZV treatment that targets a cellular metabolic mechanism essential for viral replication. The present study provided a new insight into the development of broad-spectrum antiviral agents.

News (Medical) associated with Pralatrexate

26 Jun 2024

·www.prnewswire.com

CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company

BEIJING, June 26, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, announced today that the Company is planning to submit an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration ("FDA") for CID-103 for the treatment of antibody-mediated rejection ("AMR") in kidney transplant recipients by the end of 2024. CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody recognizing a unique epitope that has demonstrated an encouraging preclinical efficacy and safety profile compared to other anti-CD38 monoclonal antibodies. The Company believes that with the proceeds from the previously announced private placement financing, together with its existing cash and cash equivalents, it will have sufficient capital to complete the Phase II clinical trial for AMR. CASI also announced that its board of directors (the "Board") received a preliminary non-binding proposal letter (the "Proposal Letter") dated June 21, 2024, from Dr. Wei-Wu He, Chairman of the Board and CEO of the Company, to acquire the entire business operations of the Company in China and all license-in, distribution and related rights in Asia (excluding Japan) related to all of the Company's pipeline products, including but not limited to EVOMELA®, FOLOTYN®, CNCT19, BI-1206, CB-5339,CID-103 and Thiotepa, for an aggregate purchase price of $40.0 million, which shall include assumption of up to $20.0 million of indebtedness of the Company (the "Proposed Transaction"). On June 25, the Board has formed a special committee comprised solely of incumbent independent directors (the "Special Committee") to evaluate the transaction contemplated under the Proposal Letter and such other strategic and business alternatives available to the Company in respect of the Company's business operations in China. The Board and the Special Committee caution the Company's shareholders and others considering trading the Company's securities that no decisions have been made with respect to the Proposed Transaction or any alternative strategic option that the Company may pursue. There can be no assurance that any definitive offer will be received, that any definitive agreement will be executed relating to the Proposed Transaction or that any other transaction will be approved or consummated. The Company does not undertake any obligation to provide any updates with respect to any transaction, except as required under applicable law. About CASI Pharmaceuticals CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market, leveraging the Company's China-based regulatory and commercial competencies and its global drug development expertise. The Company's operations in China are conducted through its wholly owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., located in Beijing, China. Forward-Looking Statements This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the business outlook and quotations from management in this announcement, as well as the Company's strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on The Nasdaq Capital Market if we fail to satisfy applicable continued listing standards; the volatility in the market price of our ordinary shares; the risk of substantial dilution of existing shareholders in future share issuances; the difficulty of executing our business strategy on a global basis including China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; legal or regulatory developments in China that adversely affect our ability to operate in China, our lack of experience in manufacturing products and uncertainty about our resources and capabilities to do so on a clinical or commercial scale; risks relating to the commercialization, if any, of our products and proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); our inability to predict when or if our product candidates will be approved for marketing by the FDA, European Medicines Agency, PRC National Medical Products Administration, or other regulatory authorities; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; the risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the risks associated with our product candidates, and the risks associated with our other early-stage products under development; the risk that result in preclinical and clinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; our ability to protect our intellectual property rights; the lack of success in the clinical development of any of our products; and our dependence on third parties; the risks related to our dependence on Juventas to conduct the clinical development of and to partner with us to co-market CNCT19; risks related to our dependence on Juventas to ensure the patent protection and prosecution for CNCT19; risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); risks relating to interests of our largest shareholder and our Chairman and CEO that differ from our other shareholders; and risks related to the development of a new manufacturing facility by CASI Pharmaceuticals (Wuxi) Co., Ltd. Further information regarding these and other risks is included in the Company's filings with the SEC. All information provided herein is as of the date of this announcement, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. COMPANY CONTACT: Rui Zhang CASI Pharmaceuticals, Inc. 240.864.2643 [email protected] SOURCE CASI Pharmaceuticals

INDPhase 2Phase 1

19 Jun 2024

·firstwordpharma.com

Dizal's JAK1 drug gets China nod for peripheral T-cell lymphoma

Chinese regulators have approved Dizal's JAK1 inhibitor golidocitinib for adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).The decision makes it "the world's first JAK1-only inhibitor" for PTCL patients, noted CEO Xiaolin Zhang, as well as the second approved drug from Dizal after the AstraZeneca spinout's lung cancer treatment sunvozertinib was waved through in China last year.While a few drugs have been granted conditional regulatory approvals in the relapsed or refractory PTCL setting, Dizal noted that their single-agent activities have been "modest," with objective response rates (ORRs) below 30%.During an advisory panel meeting last November, the FDA raised questions about accelerated approvals for Acrotech Biopharma's folate analogue inhibitor Folotyn (pralatrexate) and HDAC inhibitor Beleodaq (belinostat) in relapsed/refractory PTCL after both their confirmatory trials experienced major delays.However, Dizal says its drug has demonstrated "superior and durable" clinical benefits in the pivotal JACKPOT8B study, compared with these existing treatment options. Data from the trial presented last year showed an ORR of 44.3% with golidocitinib, including a 23.9% complete response rate.Median duration of response was 20.7 months and 53.8% of patients were still responding. Moreover, tumour responses were observed across various PTCL subtypes. Results of the JACKPOT8 trial have been published in Annals of Oncology and The Lancet Oncology."With > 200 to 400-fold selectivity over other JAK family members and ideal pharmacokinetic properties, golidocitinib exerts potent antitumour efficacy with a favourable safety profile," the company said.

Drug ApprovalAccelerated ApprovalClinical Result

08 Apr 2024

·www.prnewswire.com

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS

BEIJING, April 8, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported that it has furnished a current report on Form 6-K to disclose material development relating to its dispute with Juventas. For details, please visit below link: About CASI Pharmaceuticals CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market, leveraging the Company's China-based regulatory and commercial competencies and its global drug development expertise. The Company's operations in China are conducted through its wholly owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., located in Beijing, China. More information on CASI is available at . CASI Forward-Looking Statements: This announcement and the current report on Form 6-K contain forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the business outlook and quotations from management in this announcement and the current report on Form 6-K, as well as the Company's strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on The Nasdaq Capital Market if we fail to satisfy applicable continued listing standards; the volatility in the market price of our ordinary shares; the risk of substantial dilution of existing shareholders in future share issuances; the difficulty of executing our business strategy on a global basis including China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; legal or regulatory developments in China that adversely affect our ability to operate in China, our lack of experience in manufacturing products and uncertainty about our resources and capabilities to do so on a clinical or commercial scale; risks relating to the commercialization, if any, of our products and proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); our inability to predict when or if our product candidates will be approved for marketing by the U.S. Food and Drug Administration, European Medicines Agency, PRC National Medical Products Administration, or other regulatory authorities; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; the risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the risks associated with our product candidates, and the risks associated with our other early-stage products under development; the risk that result in preclinical and clinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; our ability to protect our intellectual property rights; the lack of success in the clinical development of any of our products; and our dependence on third parties; the risks related to our dependence on Juventas to conduct the clinical development of CNCT19 and to partner with us to co-market CNCT19; risks related to our dependence on Juventas to ensure the patent protection and prosecution for CNCT19; risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); risks relating to interests of our largest shareholder and our Chairman and CEO that differ from our other shareholders; and risks related to the development of a new manufacturing facility by CASI Pharmaceuticals (Wuxi) Co., Ltd. Further information regarding these and other risks is included in the Company's filings with the SEC. All information provided herein is as of the date of this announcement and the current report on Form 6-K, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. EVOMELA® is proprietary to Acrotech Biopharma Inc. and its affiliates. FOLOTYN® is proprietary to Acrotech Biopharma Inc and its affiliates. COMPANY CONTACT: Rui Zhang CASI Pharmaceuticals, Inc. 240.864.2643 [email protected] SOURCE CASI Pharmaceuticals

100 Deals associated with Pralatrexate

External Link

KEGG	Wiki	ATC	Drug Bank
D05589	Pralatrexate	L01BA05	DB06813

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Peripheral T-Cell Lymphoma	US	Acrotech Biopharma LLCStartup	24 Sep 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
T-Cell Lymphoma	NDA/BLA	EU	Allos Therapeutics Ltd.	-
Peripheral T-cell lymphoma unspecified recurrent	Phase 3	CN	Allos Therapeutics, Inc.	10 Sep 2015
Peripheral T-cell lymphoma unspecified recurrent	Phase 3	CN	Beijing Mengdi Pharmaceutical Co. Ltd.	10 Sep 2015
Peripheral T-cell lymphoma unspecified recurrent	Phase 3	CN	AndersonBrecon, Inc.	10 Sep 2015
Peripheral T-cell lymphoma unspecified refractory	Phase 3	CN	Beijing Mengdi Pharmaceutical Co. Ltd.	10 Sep 2015
Peripheral T-cell lymphoma unspecified refractory	Phase 3	CN	Allos Therapeutics, Inc.	10 Sep 2015
Peripheral T-cell lymphoma unspecified refractory	Phase 3	CN	AndersonBrecon, Inc.	10 Sep 2015
Cutaneous T-Cell Lymphoma	Phase 2	US	Acrotech Biopharma LLCStartup	01 Jul 2014
Mucositis	Phase 2	US	Acrotech Biopharma LLCStartup	01 Jul 2014
Anaplastic Large-Cell Lymphoma	Phase 2	US	Spectrum Pharmaceuticals, Inc.	06 Jul 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01947140 (Pubmed)	Phase 2	Peripheral T-Cell Lymphoma	14	Pralatrexate 25 mg/m2 and Romidepsin 12 mg/m2	ofhsjkpclf(hnuwlystyi) = jlwnetsntm ylggoxesim (lklretrynw ) View more	-	22 Mar 2024
NCT02594267 (Fol-CHOP, Pubmed)	Phase 1	Peripheral T-Cell Lymphoma	33	CHOP + Folotyn 30 mg/m2 (Fol-CHOP)	bhfixphyhb(hgmxlxxiho) = 21.2% gemhfdquli (eqyobmuxfu ) View more	Positive	23 Jan 2024
NCT01420679 (CTgov)	Phase 3	Peripheral T-Cell Lymphoma	21	Pralatrexate (Pralatrexate Arm)	smwpvezyci(kwowqzxxhb) = btajzuwoqb cjerdfhesc (jludkjnald, ablrligeql - fvtkwffjoa) View more	-	19 Nov 2021
NCT01420679 (CTgov)	Phase 3	Peripheral T-Cell Lymphoma	21	vitamin B12+folic acid (Observation Arm)	smwpvezyci(kwowqzxxhb) = evqmwurvea cjerdfhesc (jludkjnald, uczcmaftge - gecwytqjry) View more	-	19 Nov 2021
NCT00998946 (CTgov)	Phase 2	B-Cell Lymphoma	29	Vitamin B12+Pralatrexate	gjpqbswpla(qumpovdqlj) = mmzwefbgut caaxlyytnp (owxkdvznga, rfrwqwfivb - trgecyphky) View more	-	05 Nov 2021
NCT00052442 (CTgov)	Phase 1/2	Hodgkin's Lymphoma \| Refractory Aggressive Non-Hodgkin Lymphoma \| Non-Hodgkin's lymphoma refractory	72	pralatrexate (135 mg/m^2 Pralatrexate 1/2 Weeks)	dxrinncjfa(htvngkjhhv) = rsszwdynef lpidhmowib (cajzwjpsea, mkpjsywnbl - ldxewxuebr) View more	-	25 Aug 2021
NCT00052442 (CTgov)	Phase 1/2		72	pralatrexate (30 mg/m^2 Pralatrexate 3/4 Weeks)	dxrinncjfa(htvngkjhhv) = qlwacufdwe lpidhmowib (cajzwjpsea, cugvrpyqoh - vwhfxzftcj) View more	-	25 Aug 2021
NCT03349333 (CTgov)	Phase 3	T-cell lymphoma recurrent \| Peripheral T-cell lymphoma unspecified refractory	85	folic acid+pralatrexate	ebouhcgsam(tvukwpaojv) = ojcbjjxhkl tzhosjzhpw (jfchwcuzcu, aflxdocxik - oykylhbrlg) View more	-	12 Sep 2019
EHA2019	Not Applicable	T-cell lymphoma recurrent	22	Pralatrexate	xofxqojcns(hlbnlqdahw) = ecsotcheem unslrtsfhb (fmpohapaic ) View more	-	15 Jun 2019
EHA2019	Not Applicable	Non-Hodgkin Lymphoma	10	Pralatrexate	tvpghbpqux(srogcvnmxu) = Four patients required to be admitted at least in a cycle due to complications related to the treatment rbkmlsjzkw (rthlidxzbu ) View more	-	16 May 2019
NCT03349333 (Pubmed \| Target Oncol) Manual	Phase 3	Peripheral T-Cell Lymphoma	71	Pralatrexate	jezxvkfxub(seefebruzi) = apgsetwkww ldqtafikxn (jeomfiviyu, 40 - 64) View more	Positive	01 Apr 2019
FOT12-CN-301 (ESMO_ASIA2018)	Not Applicable	Peripheral T-Cell Lymphoma	-	Pralatrexate IV 30mg/m2/wk	nbovgmhwef(flbqfxdkfo) = yhpccdvmmn xzbgrxcawa (qiteezpfin, 40%, 64%) View more	Positive	24 Nov 2018

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis